| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell and Tumor Biology |
Division of Molecular and Cell Biology, Sunnybrook and Women's College Health Sciences Centre and Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
Requests for reprints: Jorge Filmus, Division of Molecular and Cell Biology, Sunnybrook and Women's College Health Sciences Centre, Room S-218, 2075 Bayview Avenue, M4N 3M5 Toronto, Ontario, Canada. Phone: 416-480-6100 ext. 3350; Fax: 416-480-5703; E-mail: jorge.filmus{at}swchsc.on.ca.
Glypican-3 (GPC3) is a heparan sulfate proteoglycan that is bound to the cell membrane by a glycosyl-phosphatidylinositol anchor. GPC3 is expressed by most hepatocellular carcinomas but not by normal hepatocytes and benign liver lesions. We report here that GPC3 stimulates the in vitro and in vivo growth of hepatocellular carcinoma cells by increasing autocrine/paracrine canonical Wnt signaling. Coimmunoprecipitation experiments showed that GPC3 is able to form complexes with Wnts, and cell-binding assays indicated that GPC3-expressing cells have an increased capacity to bind Wnt. Collectively, these results suggest that GPC3 stimulates Wnt activity by facilitating the interaction of this polypeptide with its signaling receptors. Surprisingly, in contrast to the current model that proposes that Wnt-glypican binding is mediated by the heparan sulfate chains, we found that the nonglycanated GPC3 core protein can form complexes with Wnts. Furthermore, we showed that the glycosaminoglycan chains are not required for the stimulatory effect on Wnt signaling and hepatocellular carcinoma growth.
This article has been cited by other articles:
|
|
 |
|
  D. Yan and X. Lin Shaping Morphogen Gradients by Proteoglycans Cold Spring Harb Perspect Biol, September 1, 2009; 1(3): a002493 - a002493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Tang and S. D. Rosen Functional Consequences of the Subdomain Organization of the Sulfs J. Biol. Chem., August 7, 2009; 284(32): 21505 - 21514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Laloo, D. Simon, V. Veillat, D. Lauzel, V. Guyonnet-Duperat, F. Moreau-Gaudry, F. Sagliocco, and C. Grosset Analysis of Post-transcriptional Regulations by a Functional, Integrated, and Quantitative Method Mol. Cell. Proteomics, August 1, 2009; 8(8): 1777 - 1788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Liu, S. Paranjpe, W. C. Bowen, A. W. Bell, J.-H. Luo, Y.-P. Yu, W. M. Mars, and G. K. Michalopoulos Investigation of the Role of Glypican 3 in Liver Regeneration and Hepatocyte Proliferation Am. J. Pathol., August 1, 2009; 175(2): 717 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ishiguro, M. Sugimoto, Y. Kinoshita, Y. Miyazaki, K. Nakano, H. Tsunoda, I. Sugo, I. Ohizumi, H. Aburatani, T. Hamakubo, et al. Anti-Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver Cancer Cancer Res., December 1, 2008; 68(23): 9832 - 9838. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Cheng, C.-J. Tseng, T. T.C. Lin, I. Cheng, H.-W. Pan, H.-C. Hsu, and Y.-M. Lee Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway Carcinogenesis, July 1, 2008; 29(7): 1319 - 1326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Kirkpatrick and S. B. Selleck Heparan sulfate proteoglycans at a glance J. Cell Sci., June 1, 2007; 120(11): 1829 - 1832. [Full Text] [PDF]
|
|
|
|
|
|
D. Williamson, J. Selfe, T. Gordon, Y.-J. Lu, K. Pritchard-Jones, K. Murai, P. Jones, P. Workman, and J. Shipley Role for Amplification and Expression of Glypican-5 in Rhabdomyosarcoma Cancer Res., January 1, 2007; 67(1): 57 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ma, S. L. Beck, R. W. Raab, R. L. McKown, G. L. Coffman, A. Utani, W. J. Chirico, A. C. Rapraeger, and G. W. Laurie Heparanase deglycanation of syndecan-1 is required for binding of the epithelial-restricted prosecretory mitogen lacritin J. Cell Biol., September 25, 2006; 174(7): 1097 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Yip, M. Smollich, and M. Gotte Therapeutic value of glycosaminoglycans in cancer. Mol. Cancer Ther., September 1, 2006; 5(9): 2139 - 2148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Komori, T. Nakatsura, S. Senju, Y. Yoshitake, Y. Motomura, Y. Ikuta, D. Fukuma, K. Yokomine, M. Harao, T. Beppu, et al. Identification of HLA-A2- or HLA-A24-Restricted CTL Epitopes Possibly Useful for Glypican-3-Specific Immunotherapy of Hepatocellular Carcinoma. Clin. Cancer Res., May 1, 2006; 12(9): 2689 - 2697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Selleck Shedding Light on the Distinct Functions of Proteoglycans Sci. Signal., April 4, 2006; 2006(329): pe17 - pe17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Capurro, W. Shi, S. Sandal, and J. Filmus Processing by Convertases Is Not Required for Glypican-3-induced Stimulation of Hepatocellular Carcinoma Growth J. Biol. Chem., December 16, 2005; 280(50): 41201 - 41206. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
